Your institution may have access to this item. Find your institution then sign in to continue.
Title
Antibody patent claims tighten.
Abstract
The article reports on U.S. court's decision in the court case AbbVie Deutschland v. Janssen Biotech and Centocor Biologics where the court ruled that Janssen's Stelara (ustekinumab), a interleukin (IL)-12-neutralizing antibody product did not infringe pharmaceutical firm AbbVie's patent claims.